Variables | All treatments | P value | Artemether-lumefantrine | P value | Artesunate-amodiaquine | P value | ||||
---|---|---|---|---|---|---|---|---|---|---|
2009–2010 (n = 743) | 2014–2015 (n = 598) | All (n = 1341) | 2009–2010 (n = 360) | 2014–2015 (n = 303) | 2009–2010 (n = 384) | 2014–2015 (n = 295) | ||||
Clinical response | ||||||||||
 FCT (day) | ||||||||||
  Mean | 1.1 | 1.2 | 1.2 | 0.002 | 1.1 | 1.3 | 0.002 | 1.1 | 1.1 | 0.36 |
  95% CI | 1.08–1.14 | 1.2–1.3 | 1.1–1.2 |  | 1.1–1.2 | 1.2–1.4 |  | 1.05–1.12 | 1.1–1.2 |  |
Parasitological responses | ||||||||||
 APPD1 (%) | 398 (53.6) | 370 (61.9) | 768 (57.3) | 0.002 | 210 (58.3) | 199 (65.7) | 0.06 | 188 (49.1) | 171 (58) | 0.02 |
 APPD2 (%) | 38 (5.1) | 153 (25.6) | 191 (14.2) | <  0.0001 | 21 (5.8) | 83 (27.4) | <  0.0001 | 17 (4.4) | 70 (23.7) | <  0.0001 |
 APPD3 (%) | 7 (0.9) | 14 (2.3) | 21 (1.6) | 0.07 | 2 (0.6) | 9 (3) | 0.03 | 5 (1.3) | 5 (1.7) | 0.92 |
PRRD1 | ||||||||||
 Geometric mean | 444 | 409 | 428 | 0.75 | 318 | 270 | 0.63 | 609 | 627 | 0.86 |
 95% CI | 349–565 | 315–531 | 359–511 |  | 222–454 | 186–391 |  | 440–841 | 438–898 |  |
PRRD2 | ||||||||||
 Geometric mean | 7594 | 11136 | 4723 | <  0.0001 | 11112 | 4439 | 0.0002 | 11 158 | 5034 | 0.007 |
 95% CI | 6709–8597 | 9742–12729 | 3802–5868 |  | 9092–13 581 | 3276–6016 |  | 9335–13 337 | 3691–6864 |  |
PCT (day) | ||||||||||
 Mean | 1.6 | 1.9 | 1.8 | <  0.0001 | 1.7 | 2 | <  0.0001 | 1.6 | 1.9 | <  0.0001 |
 95% CI | 1.55–1.64 | 1.9–2.0 | 1.7–1.8 |  | 1.6–1.7 | 1.9–2.1 |  | 1.5–1.6 | 1.8–2.0 |  |
Haematological response | ||||||||||
 AnRT (day) | ||||||||||
  Mean | 10.6 | 10.1 | 10.4 | 0.53 | 11.1 | 11 | 0.9 | 10 | 9.2 | 0.4 |
  95% CI | 9.7–11.5 | 9.0–11.2 | 9.7–11.1 |  | 9.8–12.5 | 9.3–12.8 |  | 8.8–11.3 | 7.8–10.7 |  |